CRITICAL CARE PORTFOLIO

You are here:
  • Critical Care

    FAVIBEST

    Favipiravir

    Favipiravir (6-Fluoro-3-hydroxypyrazine-2-carboxamide) is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to…

    Know More